

*Correction*

**Correction: Kikuchi, K., et al., Potential of the Angiotensin Receptor Blockers (ARBs) Telmisartan, Irbesartan, and Candesartan for Inhibiting the HMGB1/RAGE Axis in Prevention and Acute Treatment of Stroke.**  
***Int. J. Mol. Sci.* 2013, 14, 18899–18924.**

Kiyoshi Kikuchi <sup>1,2,3</sup>, Salunya Tancharoen <sup>1</sup>, Takashi Ito <sup>4</sup>, Yoko Morimoto-Yamashita <sup>5</sup>, Naoki Miura <sup>6</sup>, Ko-ichi Kawahara <sup>7</sup>, Ikuro Maruyama <sup>4</sup>, Yoshinaka Murai <sup>2</sup> and Eiichiro Tanaka <sup>2,\*</sup>

<sup>1</sup> Department of Pharmacology, Faculty of Dentistry, Mahidol University, 6 Yothe Road, Rajthevee, Bangkok 10400, Thailand; E-Mails: kikuchi\_kiyoshi@kurume-u.ac.jp (K.K.); salunya.tan@mahidol.ac.th (S.T.)

<sup>2</sup> Division of Brain Science, Department of Physiology, Kurume University School of Medicine, 67 Asahi-machi, Kurume 830-0011, Japan; E-Mail: ymurai@med.kurume-u.ac.jp

<sup>3</sup> Department of Neurosurgery, Kurume University School of Medicine, 67 Asahi-machi, Kurume 830-0011, Japan

<sup>4</sup> Department of Systems Biology in Thromboregulation, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima 890-8520, Japan; E-Mails: takashi@m3.kufm.kagoshima-u.ac.jp (T.I.); rinken@m3.kufm.kagoshima-u.ac.jp (I.M.)

<sup>5</sup> Department of Restorative Dentistry and Endodontology, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima 890-8544, Japan; E-Mail: yokomaru@dent.kagoshima-u.ac.jp

<sup>6</sup> Laboratory of Diagnostic Imaging, Department of Veterinary Science, Faculty of Agriculture, Kagoshima University, 1-21-24 Korimoto, Kagoshima 890-0065, Japan; E-Mail: nm18@vet.kagoshima-u.ac.jp

<sup>7</sup> Laboratory of Functional Foods, Department of Biomedical Engineering Osaka Institute of Technology, 5-16-1 Omiya, Asahi Ward, Osaka 535-8585, Japan; E-Mail: kawahara@bme.oit.ac.jp

\* Author to whom correspondence should be addressed; E-Mail: eacht@med.kurume-u.ac.jp; Tel.: +81-942-31-7542; Fax: +81-942-31-7695.

*Received: 3 March 2014 / Accepted: 3 March 2014 / Published: 27 March 2014*

---

The original version of the paper [1] reports that “*This ACTIVE I study was supported by Pfizer*” (Page 18905). However, the sponsors of the ACTIVE I study were actually Bristol-Myers Squibb and Sanofi-Aventis rather than Pfizer. Therefore, we would like to correct the wording to read: “*This ACTIVE I study was supported by Bristol-Myers Squibb and Sanofi-Aventis*”. The authors apologize for any inconvenience this may have caused to the readers of this journal.

## **Reference**

1. Kikuchi, K.; Tanchaen, S.; Ito, T.; Morimoto-Yamashita, Y.; Miura, N.; Kawahara, K.-I.; Maruyama, I.; Murai, Y.; Tanaka, E. Potential of the Angiotensin Receptor Blockers (ARBs) Telmisartan, Irbesartan, and Candesartan for Inhibiting the HMGB1/RAGE Axis in Prevention and Acute Treatment of Stroke. *Int. J. Mol. Sci.* **2013**, *14*, 18899–18924.

© 2014 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (<http://creativecommons.org/licenses/by/3.0/>).